BEAM
Price
$24.49
Change
+$0.10 (+0.41%)
Updated
Oct 2, 04:59 PM (EDT)
Capitalization
2.5B
38 days until earnings call
Intraday BUY SELL Signals
RGNX
Price
$7.42
Change
-$0.00 (-0.00%)
Updated
Oct 2, 04:59 PM (EDT)
Capitalization
493.12M
40 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

BEAM vs RGNX

BEAM vs RGNX Comparison Chart in %
loading
loading
View a ticker or compare two or three
VS
BEAM vs. RGNX commentary
Oct 02, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is BEAM is a Hold and RGNX is a Hold.

Interact to see
Advertisement
SUMMARIES
Loading...
FUNDAMENTALS RATINGS
BEAM vs RGNX: Fundamental Ratings
BEAM
RGNX
OUTLOOK RATING
1..100
961
VALUATION
overvalued / fair valued / undervalued
1..100
26
Undervalued
83
Overvalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
9299
PRICE GROWTH RATING
1..100
6484
P/E GROWTH RATING
1..100
10017
SEASONALITY SCORE
1..100
50n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

BEAM's Valuation (26) in the null industry is somewhat better than the same rating for RGNX (83) in the Biotechnology industry. This means that BEAM’s stock grew somewhat faster than RGNX’s over the last 12 months.

BEAM's Profit vs Risk Rating (100) in the null industry is in the same range as RGNX (100) in the Biotechnology industry. This means that BEAM’s stock grew similarly to RGNX’s over the last 12 months.

BEAM's SMR Rating (92) in the null industry is in the same range as RGNX (99) in the Biotechnology industry. This means that BEAM’s stock grew similarly to RGNX’s over the last 12 months.

BEAM's Price Growth Rating (64) in the null industry is in the same range as RGNX (84) in the Biotechnology industry. This means that BEAM’s stock grew similarly to RGNX’s over the last 12 months.

RGNX's P/E Growth Rating (17) in the Biotechnology industry is significantly better than the same rating for BEAM (100) in the null industry. This means that RGNX’s stock grew significantly faster than BEAM’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
BEAMRGNX
RSI
ODDS (%)
Bullish Trend 2 days ago
88%
Bullish Trend 2 days ago
87%
Stochastic
ODDS (%)
Bullish Trend 2 days ago
78%
Bullish Trend 2 days ago
86%
Momentum
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
89%
MACD
ODDS (%)
Bullish Trend 2 days ago
87%
Bullish Trend 2 days ago
71%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
82%
Bullish Trend 2 days ago
81%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
82%
Bearish Trend 2 days ago
86%
Advances
ODDS (%)
Bullish Trend 11 days ago
77%
Bullish Trend 5 days ago
81%
Declines
ODDS (%)
Bearish Trend 2 days ago
84%
Bearish Trend 9 days ago
85%
BollingerBands
ODDS (%)
Bullish Trend 2 days ago
87%
Bullish Trend 2 days ago
75%
Aroon
ODDS (%)
Bearish Trend 2 days ago
82%
Bearish Trend 2 days ago
83%
COMPARISON
Comparison
Oct 02, 2026
Stock price -- (BEAM: $24.39 vs. RGNX: $7.42)
Brand notoriety: BEAM and RGNX are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: BEAM: 88% vs. RGNX: 106%
Market capitalization -- BEAM: $2.5B vs. RGNX: $493.12M
BEAM [@Biotechnology] is valued at $2.5B. RGNX’s [@Biotechnology] market capitalization is $493.12M. The market cap for tickers in the [@Biotechnology] industry ranges from $58 to $133.74B. The average market capitalization across the [@Biotechnology] industry is $2.21B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

BEAM’s FA Score shows that 1 FA rating(s) are green while RGNX’s FA Score has 1 green FA rating(s).

  • BEAM’s FA Score: 1 green, 4 red.
  • RGNX’s FA Score: 1 green, 4 red.
According to our system of comparison, BEAM is a better buy in the long-term than RGNX.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

BEAM’s TA Score shows that 5 TA indicator(s) are bullish while RGNX’s TA Score has 5 bullish TA indicator(s).

  • BEAM’s TA Score: 5 bullish, 6 bearish.
  • RGNX’s TA Score: 5 bullish, 4 bearish.
According to our system of comparison, RGNX is a better buy in the short-term than BEAM.

Price Growth

BEAM (@Biotechnology) experienced а -1.09% price change this week, while RGNX (@Biotechnology) price change was +2.49% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -3.63%. For the same industry, the average monthly price growth was -14.35%, and the average quarterly price growth was -1.64%.

Reported Earning Dates

BEAM is expected to report earnings on Nov 09, 2026.

RGNX is expected to report earnings on Nov 11, 2026.

Industries' Descriptions

@Biotechnology (-3.63% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

View a ticker or compare two or three
BEAM
Daily Signal:
Gain/Loss:
RGNX
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
CRWU36.410.95
+2.68%
T-REX 2X Long CRWV Daily Target ETF
KIQQ25.180.04
+0.16%
KraneShares InspereX Nasdaq Dynamic Buffered High Income Index ETF (KIQQ)
HAWX45.32-0.08
-0.18%
iShares Currency Hedged MSCI ACWI ex U.S. ETF (HAWX)
IEV70.06-1.07
-1.50%
iShares Europe ETF (IEV)
GNOM68.78-1.70
-2.41%
Global X Genomics & Biotechnology ETF (GNOM)

RGNX and

Correlation & Price change

A.I.dvisor indicates that over the last year, RGNX has been loosely correlated with BEAM. These tickers have moved in lockstep 49% of the time. This A.I.-generated data suggests there is some statistical probability that if RGNX jumps, then BEAM could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To RGNX
1D Price
Change %
RGNX100%
-1.46%
BEAM - RGNX
49%
Loosely correlated
-0.25%
AXON - RGNX
48%
Loosely correlated
-0.07%
RCKT - RGNX
48%
Loosely correlated
-1.52%
CRSP - RGNX
47%
Loosely correlated
+0.22%
FDMT - RGNX
46%
Loosely correlated
-3.28%
More